Similar Search Results

Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A reexamination using data from the U.S. and Australia

Lichtenberg, Frank R. - 2010

Previous investigators argued that increasing 5-year survival for cancer patients should not be taken as evidence of improved prevention, screening, or therapy, because they found little correlation between the change in 5-year survival for a specific tumor and the change in tumor-related...

Persistent link: https://www.econbiz.de/10012462603

The Impact of Increased Utilization of HIV Drugs on Longevity and Medical Expenditures : An Assessment Based on Aggregate U.S. Time-Series Data

Lichtenberg, Frank R. - 2006

Estimates of mortality models imply that actual life expectancy of HIV/AIDS patients in 2001 was 13.4 years higher than it would have been if the drug utilization rate had not increased from its 1993 level. Estimates of a model of hospital discharges imply that increased utilization of HIV drugs...

Persistent link: https://www.econbiz.de/10012466259

The Dual Effects of Intellectual Property Regulations : Within- and Between- Patent Competition in the US Pharmaceuticals Industry

Lichtenberg, Frank R. - 2002

A patent only protects an innovator from others producing the same product, but it does not protect him from others producing better products under new patents. Therefore, one may divide up the source of competition facing an innovator into within-patent competition, which results from...

Persistent link: https://www.econbiz.de/10012469403

Sources of U.S. Longevity Increase, 1960-1997

Lichtenberg, Frank R. - 2002

models using annual U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual … data are available for only one type of innovation - new drugs - but pharmaceutical R&D accounts for a significant fraction … innovation (in the form of new drug approvals) and expenditure on medical care (especially public expenditure) contributed to …

Persistent link: https://www.econbiz.de/10012469960

The Effects of Mergers on Prices, Costs, and Capacity Utilization in the U.S. Air Transportation Industry, 1970-84

Lichtenberg, Frank R. - 1989

We analyze the effect of mergers on various aspects of airline performance during the period 1970-84, using a panel data set constructed by Caves et al. Estimates derived from a simple "matched pairs" statistical model indicate that these mergers were associated with reductions in unit cost. The...

Persistent link: https://www.econbiz.de/10012475840

The Impact of Public and Private Research Support on Premature Cancer Mortality and Hospitalization in the U.S., 1999-2013

Lichtenberg, Frank R. - 2017

The estimates indicate that cancer sites about which more research-supported articles were published since the 1970s had larger reductions in premature mortality and hospitalization during the period 1999-2013, controlling for the change in the number of people diagnosed. Cancer sites for which...

Persistent link: https://www.econbiz.de/10012455440

The Effects of Off-label Drug Use on Disability and Medical Expenditure

Blankart, Katharina; Lichtenberg, Frank R. - National Bureau of Economic Research - 2022

-label have on average $515 higher medical expenditure and work-loss cost. Pharmaceutical innovation has direct and indirect …

Persistent link: https://www.econbiz.de/10013388796

Has medical innovation reduced cancer mortality?

Lichtenberg, Frank R. - 2010

I analyze the effects of four types of medical innovation and cancer incidence on U.S. cancer mortality rates during …Under the assumption that there were no pre-dated factors that drove both innovation and mortality and that there would … have been parallel trends in mortality in the absence of innovation, the estimates indicate that there were three major …

Persistent link: https://www.econbiz.de/10012462770

Pharmaceutical innovation and the longevity of Australians : a first look

Lichtenberg, Frank R. - 2008

We examine the impact of pharmaceutical innovation on the longevity of Australians during the period 1995-2003. Due to …

Persistent link: https://www.econbiz.de/10012464638

Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003

Lichtenberg, Frank R. - 2008

Countries with larger increases in the share of cardiovascular drug doses that contained post-1990 or post-1995 ingredients had smaller increases in the cardiovascular disease hospital discharge rate, controlling for the quantity of cardiovascular medications consumed per person, the use of...

Persistent link: https://www.econbiz.de/10012464639